Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Peptides by Human-Data Status

A reader's filter for evidence-base maturity. Approved → known human-trial data → preclinical-only.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

Human-data status is the single most useful filter for interpreting peptide claims. A peptide with human RCT data has been observed in people — not just in cell cultures or rodent models. A peptide with no human data has, by definition, an untested human safety and efficacy profile, regardless of how many in-vitro or animal papers are cited in its marketing. Approval status is a separate axis: a compound can have human trial data and an FDA label (tesamorelin: Egrifta SV, DailyMed set id 3d783378, and Egrifta WR, set id 839334d3, both effective 29 July 2026; bremelanotide: Vyleesi, set id f1d0c1b5, effective 13 November 2025) while the MHRA’s GLP-1 page (updated 5 February 2026) lists tirzepatide (Mounjaro) among licensed GLP-1 medicines. See human data vs preclinical data for the underlying distinction.

PeptideHuman dataUK approvalClassGradeMain uncertainty
BPC-157 — Body Protection Compound 157limitednot-approvedTissue RepairCHuman clinical evidence is limited or not established; published evidence is mostly preclinical.
Cerebrolysin — Porcine-Brain Neuropeptide Preparationlimitednot-approvedNeuropeptideBHuman trials exist; benefit beyond the people and conditions studied is not established.
CJC-1295 — GHRH(1-29) Analogue (no DAC / DAC variants)limitednot-approvedGHRH AnalogueBHuman trials exist; benefit beyond the people and conditions studied is not established.
DSIP — Delta Sleep-Inducing Peptidelimitednot-approvedNeuropeptideBHuman trials exist; benefit beyond the people and conditions studied is not established.
Epitalon — Pineal Tetrapeptide Bioregulatorlimitednot-approvedKhavinson BioregulatorBHuman trials exist; benefit beyond the people and conditions studied is not established.
GHK-Cu — Copper Tripeptide-1limitednot-approvedTissue RepairBHuman trials exist; benefit beyond the people and conditions studied is not established.
GHRP-2 — Growth Hormone Releasing Peptide 2 (Research Evidence Summary)limitednot-approvedGH Secretagogue (GHRP)BHuman trials exist; benefit beyond the people and conditions studied is not established.
Ipamorelin — Selective Growth Hormone Secretagoguelimitednot-approvedGH Secretagogue (GHRP)BHuman trials exist; benefit beyond the people and conditions studied is not established.
Kisspeptin-10 — GnRH-Axis Hypothalamic Decapeptidelimitednot-approvedKisspeptin FamilyBHuman trials exist; benefit beyond the people and conditions studied is not established.
LL-37 — Human Cathelicidin Antimicrobial Peptidelimitednot-approvedAntimicrobial / CathelicidinBHuman trials exist; benefit beyond the people and conditions studied is not established.
Melanotan II — Broad-Spectrum α-MSH Analoguelimitednot-approvedMelanocortinBHuman trials exist; benefit beyond the people and conditions studied is not established.
Pinealon — Pineal Tripeptide Bioregulatorlimitednot-approvedKhavinson BioregulatorBHuman trials exist; benefit beyond the people and conditions studied is not established.
Retatrutide — Triple GIP/GLP-1/Glucagon Receptor Agonistlimitednot-approvedIncretin (GLP-1 / GIP / Glucagon)BHuman trials exist; benefit beyond the people and conditions studied is not established.
Selank — Tuftsin-Derivative Anxiolytic Heptapeptidelimitednot-approvedNeuropeptideBHuman trials exist; benefit beyond the people and conditions studied is not established.
Semax — ACTH(4-10) Heptapeptide Nootropiclimitednot-approvedNeuropeptideBHuman trials exist; benefit beyond the people and conditions studied is not established.
TB-500 — Thymosin β-4 Fragment (Ac-LKKTETQ)limitednot-approvedTissue RepairCHuman clinical evidence is limited or not established; published evidence is mostly preclinical.
Thymalin — Thymic Peptide Complex Bioregulatorlimitednot-approvedThymic PeptideBHuman trials exist; benefit beyond the people and conditions studied is not established.
Thymosin α-1 — Thymic Immunomodulatory Peptide (Zadaxin / Thymalfasin)limitednot-approvedThymic PeptideBHuman trials exist; benefit beyond the people and conditions studied is not established.
AOD-9604 — Growth Hormone C-terminal Lipolytic Fragmentnonot-approvedGH Lipolytic FragmentCHuman clinical evidence is limited or not established; published evidence is mostly preclinical.
Cagrilintide — Long-Acting Amylin Analogue (Research Evidence Summary)nonot-approvedIncretin (GLP-1 / GIP / Glucagon)CHuman clinical evidence is limited or not established; published evidence is mostly preclinical.
Humanin — Mitochondrial-Derived 24-Amino-Acid Peptidenonot-approvedMitochondrial PeptideCHuman clinical evidence is limited or not established; published evidence is mostly preclinical.
KPV — α-MSH(11-13) C-Terminal Tripeptidenonot-approvedMelanocortinCHuman clinical evidence is limited or not established; published evidence is mostly preclinical.
MK-677 (Ibutamoren) — Oral Ghrelin-Receptor Agonist (Research Evidence Summary)nonot-approvedGH Secretagogue (GHRP)CHuman clinical evidence is limited or not established; published evidence is mostly preclinical.
MOTS-c — Mitochondrial Open Reading Frame 12S rRNA-cnonot-approvedMitochondrial PeptideCHuman clinical evidence is limited or not established; published evidence is mostly preclinical.
PT-141 (Bremelanotide) — Melanocortin Receptor Agonist (Vyleesi)yesunclearMelanocortinBFDA-approved as Vyleesi (bremelanotide; DailyMed label effective 13 November 2025) for premenopausal women with acquired, generalized hypoactive sexual desire disorder. No UK marketing authorisation found in an eMC search (3 November 2026); eMC is not a complete UK register.
Semaglutide — GLP-1 Receptor Agonist (Research Evidence Summary)yesapprovedIncretin (GLP-1 / GIP / Glucagon)ALicensed in the UK as Wegovy, Ozempic and Rybelsus according to the MHRA (page updated 5 February 2026). Off-label or off-indication use is not within the licensed evidence base.
SS-31 (Elamipretide) — Cardiolipin-Targeted Mitochondrial PeptideyesunclearMitochondrial PeptideBFDA accelerated approval as Forzinity (elamipretide; DailyMed label effective 10 December 2025) to improve muscle strength in adult and paediatric patients with Barth syndrome who weigh at least 30 kg. No UK marketing authorisation found in an eMC search (3 November 2026); eMC is not a complete UK register.
Tesamorelin — Stabilised GHRH Analogue (EGRIFTA)yesunclearGHRH AnalogueBFDA-approved as Egrifta SV and Egrifta WR (DailyMed labels effective 29 July 2026) to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. No UK marketing authorisation found in an eMC search (3 November 2026); eMC is not a complete UK register.
Tirzepatide — Dual GIP/GLP-1 Receptor Agonist (Mounjaro / Zepbound)yesapprovedIncretin (GLP-1 / GIP / Glucagon)ALicensed in the UK as Mounjaro according to the MHRA (page updated 5 February 2026). Off-label or off-indication use is not within the licensed evidence base.
Published: 2026-06-20Last updated: 2026-11-06

If you spot an error or have new evidence to suggest, please use our corrections policy.